AKT1 and gastric cancer: Mechanistic investigations concluded that DARPP-32 promotion of EGFR/ERBB3 protein interaction leads to EGFR phosphorylation and activation of PI3K-AKT signaling, thereby increasing cell survival and gefitinib resistance in gastric cancer cells [53].